A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

This Phase III study is testing a new drug called ESG401 against standard chemotherapy in people with triple-negative breast cancer (TNBC) that has spread (metastatic) or cannot be removed surgically and has either not responded to immunotherapy or is not eligible for it. **You may be eligible if...** - You are 18 or older - You have confirmed triple-negative breast cancer (TNBC) - Your cancer is newly metastatic or returned more than 6 months after completing curative-intent treatment - You have not received prior systemic treatment for metastatic disease - Your tumor is either PD-L1 negative, or you had PD-1/PD-L1 treatment for early-stage disease that failed, or you cannot have immunotherapy due to other health reasons - You have measurable disease on imaging **You may NOT be eligible if...** - You have already received treatment for metastatic TNBC - You have active brain metastases - You have serious organ dysfunction or other active cancers Talk to your doctor to see if this trial is right for you.